UNSPSC 51271904: Benoxinate or oxybuprocaine

This classification denotes an anesthetic agent with the molecular formula C17H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AXQ0JYM303, chemically known as benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci) but generally known as benoxinate, which bears US NIH Compound Identifier 4633. Benoxinate most often comes in base and hydrochloride forms. European Medicines Agency schedules Oxybuprocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09557MIG.

UNSPSC 51271904 Benoxinate or oxybuprocaine is a Commodity code representing local anesthetic ophthalmic products that state and local governments procure as components within broader pharmaceutical and over-the-counter (OTC) product contracts. The code does not appear in isolation in recent state and local solicitations; instead, benoxinate and similar pharmaceuticals are bundled into multi-source generic drug procurement vehicles managed through cooperative purchasing alliances. State and local issuers soliciting under this code include state departments of administration and state health agencies, typically procuring on behalf of statewide networks of government facilities, hospitals, clinics, and institutional healthcare settings that serve public populations. The work involves establishing supply agreements with pharmaceutical manufacturers or authorized distributors to ensure reliable, competitively priced inventory of FDA-regulated pharmaceutical products meeting current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, with a March 26, 2026, response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products. Awarded vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three with chargeback systems in place. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. Evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, EDI capability at 5 percent, administrative fee format compliance at 5 percent, and agreement to a 3 percent administrative fee at 5 percent. The RFP covers participating states and local government facilities, including Oregon, with a two-year initial contract term and optional extensions at MMCAP's sole discretion. No specific set-aside designations or restrictions for disadvantaged enterprises are identified in the available documentation. Geographic activity centers on the Upper Midwest and Pacific Northwest through the MMCAP consortium, though the recent opportunity block provides no other state-level pharmaceutical procurement examples under this specific commodity code.